AE Wealth Management LLC purchased a new stake in shares of Express Scripts Holding Co (NASDAQ:ESRX) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 2,651 shares of the company’s stock, valued at approximately $205,000.
A number of other hedge funds and other institutional investors have also modified their holdings of the business. Abrams Capital Management L.P. bought a new position in shares of Express Scripts in the second quarter worth approximately $204,846,000. Canada Pension Plan Investment Board grew its holdings in shares of Express Scripts by 124.5% in the second quarter. Canada Pension Plan Investment Board now owns 1,971,200 shares of the company’s stock worth $152,196,000 after purchasing an additional 1,093,200 shares during the last quarter. Farallon Capital Management LLC bought a new position in shares of Express Scripts in the first quarter worth approximately $71,843,000. FMR LLC grew its holdings in shares of Express Scripts by 117.6% in the second quarter. FMR LLC now owns 1,419,840 shares of the company’s stock worth $109,626,000 after purchasing an additional 767,426 shares during the last quarter. Finally, Bank of Montreal Can bought a new stake in Express Scripts in the second quarter valued at $54,695,000. Institutional investors and hedge funds own 84.73% of the company’s stock.
NASDAQ:ESRX opened at $95.23 on Tuesday. The firm has a market capitalization of $50.57 billion, a P/E ratio of 13.41, a P/E/G ratio of 1.13 and a beta of 1.00. Express Scripts Holding Co has a twelve month low of $55.80 and a twelve month high of $96.45. The company has a current ratio of 0.71, a quick ratio of 0.59 and a debt-to-equity ratio of 0.69.
Express Scripts (NASDAQ:ESRX) last announced its quarterly earnings data on Wednesday, August 1st. The company reported $2.22 EPS for the quarter, beating the consensus estimate of $2.20 by $0.02. The business had revenue of $25.64 billion during the quarter, compared to analyst estimates of $25.43 billion. Express Scripts had a return on equity of 25.49% and a net margin of 4.65%. The company’s revenue for the quarter was up 1.2% on a year-over-year basis. During the same quarter last year, the firm posted $1.73 earnings per share. analysts predict that Express Scripts Holding Co will post 9.07 earnings per share for the current fiscal year.
ESRX has been the topic of several recent analyst reports. BidaskClub upgraded shares of Express Scripts from a “hold” rating to a “buy” rating in a report on Tuesday, May 22nd. Zacks Investment Research upgraded shares of Express Scripts from a “strong sell” rating to a “hold” rating in a report on Tuesday, June 26th. Royal Bank of Canada lifted their price target on shares of Express Scripts to $94.00 and gave the company an “outperform” rating in a report on Monday, August 27th. William Blair upgraded shares of Express Scripts from a “market perform” rating to an “outperform” rating in a report on Wednesday, August 1st. Finally, Robert W. Baird cut shares of Express Scripts from an “outperform” rating to a “neutral” rating and set a $81.00 price target on the stock. in a report on Friday, July 20th. Three research analysts have rated the stock with a sell rating, eleven have given a hold rating and six have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $85.58.
In other Express Scripts news, insider Christine Houston sold 12,898 shares of the firm’s stock in a transaction on Friday, August 10th. The stock was sold at an average price of $85.00, for a total transaction of $1,096,330.00. Following the completion of the transaction, the insider now owns 110,908 shares of the company’s stock, valued at $9,427,180. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.79% of the company’s stock.
About Express Scripts
Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States and Canada. The company's PBM segment offers clinical solutions; and specialized pharmacy care, home delivery and specialty pharmacy, retail network pharmacy administration, benefit design consultation, drug utilization review, drug formulary management, public exchange, administration of group purchasing organization, and digital consumer health and drug information services.
See Also: What is the S&P 500 Index?
Receive News & Ratings for Express Scripts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Express Scripts and related companies with MarketBeat.com's FREE daily email newsletter.